About SOM Biotech
SOM Biotech is a company based in Barcelona (Spain) founded in 2009 by Raul Insa. SOM Biotech has raised $28.52 million across 3 funding rounds from investors including European Investment Bank and Prevail Partners. SOM Biotech offers products and services including SOM AI PRO and SOM3355. SOM Biotech operates in a competitive market with competitors including Biogen, GSK, Denali Therapeutics, Avidity Biosciences and Annexon, among others.
- Headquarter Barcelona, Spain
- Founders Raul Insa
- SectorsHealthcare
- Email••••••••
- Website sombiotech.com
- Social LinkedIn X
- Legal Name Som Innovation Biotech S.A.
- Total Equity Funding$28.52M (USD)
in 3 rounds
- Latest Funding Round$18.49M (USD), Series B
Dec 2023
- InvestorsEuropean Investment Bank
& 1 more
Products & Services of SOM Biotech
SOM Biotech offers a comprehensive portfolio of products and services, including SOM AI PRO and SOM3355.
Proprietary AI tool for predicting drug efficacy in rare disorders
Treatment for movement and psychiatric disorders in Huntington's Disease
Funding Insights of SOM Biotech
SOM Biotech has successfully raised a total of $28.52M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $18.49 million completed in December 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $28.52M
- Total Rounds 3
- Last Round Series B — $18.49M
- First Round $2.14M
(Jan 2017)
- Investors Count 2
All 3 funding rounds of SOM Biotech with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2023 | $18.49M | Series B | – | European Investment Bank, Prevail Partners | – |
| Mar 2019 | $7.89M | Series A | – | – | – |
| Jan 2017 | $2.14M | Seed | – | – | – |
2 investors in total: 2 institutional.
Investors in SOM Biotech
SOM Biotech has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include European Investment Bank and Prevail Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Finance and advisory services for infrastructure projects are provided. | 1958 | eib.org | Luxembourg, Luxembourg | |
Limited information is provided about Prevail Partners' activities. | – | prevailpartners.com | - |
Investor details for SOM Biotech
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of SOM Biotech
6 people are tracked at SOM Biotech (4 in leadership, 2 in team).
| Name | Role | Group |
|---|---|---|
Raul Insa | Founder & CEO | Leadership |
Kevin McAllister | Interim Chief Scientific Officer | Leadership |
Raúl Insa | Chief Executive Officer | Leadership |
Oscar Huertas | Chief Technology Officer | Leadership |
Anna Ribosa de Gràcia | Executive Assistant & Office Manager | Team |
Gal.la Pericot Mohr | R&D Manager | Team |
Complete people profiles for SOM Biotech
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of SOM Biotech
3 dated milestones of SOM Biotech across 14 years, from founding to its latest funding, stage changes and deals.
- Founded SOM Biotech is founded.
- Funding First funding round of $2.1M.
- Funding Latest funding round, Series B, of $18.5M.
Competitors of SOM Biotech
SOM Biotech operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biogen, GSK, Denali Therapeutics, Avidity Biosciences and Annexon, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| biogen.com | 1978 | Cambridge, United States | $80M | 1 | Therapies for neurodegenerative and immunology disorders are developed. | |
| gsk.com | 1715 | Brentford, United Kingdom | – | 90,913 | Developer of pharmaceuticals and vaccines for various therapeutic areas | |
| denalitherapeutics.com | 2015 | San Francisco, United States | $347M | 377 | Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's. | |
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. | |
| annexonbio.com | 2011 | San Francisco, United States | $256M | 80 | Developer of antibodies to treat complement-mediated neurodegenerative diseases | |
| ultragenyx.com | 2010 | Novato, United States | $135.1M | 837 | Therapeutics for rare and ultra-rare metabolic diseases are developed. | |
| alnylam.com | 2002 | Cambridge, United States | $17M | 2,100 | RNA interference-based therapeutics are developed for multiple disorders. | |
| sutrobio.com | 2003 | United States | $171.85M | 235 | Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | |
| geminitherapeutics.com | 2015 | Cambridge, United States | $44.5M | 45 | Developer of precision therapeutics for dry AMD and rare genetic diseases | |
| antheia.bio | 2013 | Palo Alto, United States | $152.37M | 50 | Yeast cells are genetically engineered to produce medicinal products. |
Detailed competitors of SOM Biotech
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of SOM Biotech
The website of SOM Biotech (sombiotech.com) receives about 1K visits a month.
- Monthly visits1K
▲ 21.9% vs previous month
Websites whose visitors overlap most with SOM Biotech. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| youtube.com | 100% | 30.4B | #2 | View details |
Latest news on Som Biotech
Complete news archive for SOM Biotech
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to SOM Biotech
10 companies that operate in the same segment as SOM Biotech (Life Sciences Platforms & Tools), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | – | – | |
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | – | – | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M | – | – | |
Electron microscopy services and microanalysis instruments are provided. | 1956 | Waltham, Massachusetts, United States | – | USD 44.56 B | 125,000 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
A platform for sharing and accessing academic research papers is provided. | 2008 | San Francisco, California, United States | USD 58.4 M | – | – | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about SOM Biotech
SOM Biotech was founded in 2009 and raised its 1st funding round 8 years after it was founded.
SOM Biotech is headquartered in Barcelona, Spain. It is registered at Barcelona, Catalonia, Spain.
Raul Insa is the current CEO of SOM Biotech. They have also founded this company.
SOM Biotech is a funded company, having raised a total of $28.52M across 3 funding rounds to date. The company's 1st funding round was a Seed of $2.14M, raised on Jan 2017.
Founded in 2009 and based in Barcelona, Spain, SOM Biotech operates in the biotechnology sector, focusing on rare disease treatments. A ligand-based in-silico platform is utilized for virtual compound screening to build a drug pipeline. This includes SOM0226 in phase II for TTR amyloidosis and SOM3355 in phase II for Huntingtons disease, alongside candidates targeting cystic fibrosis, glioblastoma, and Alzheimers disease.
SOM Biotech's top competitors include Alnylam, Sutro Biopharma and Annexon.
SOM Biotech offers SOM AI PRO and SOM3355.
SOM Biotech has 2 investors. Key investors include European Investment Bank, and Prevail Partners.
SOM Biotech operates through Som Innovation Biotech S.A..